Bristol Myers Squibb announced that its combination of Opdivo and Yervoy has successfully met the main goal in a late-stage study for liver cancer treatment. The positive results from the CheckMate-9DW study have generated excitement for the full data release. The combination was evaluated as a first-line and initial treatment for a type of liver cancer, showing promise in improving patient outcomes. The success of Yervoy in the trial has surprised many, especially after a previous Opdivo setback in liver cancer.
Roche autoimmune disease drug disappoints in closely watched trial https://t.co/eTesDKZkwS $RHHBY $ARGX $IMVT $TRML $JNJ
I sort of really like the forward catalyst path for $ARGX and $IMVT. First, we get the $BHVN overhang removed... and then you can own both for the buyout again and might get a few positive clinical catalysts. I firmly believe that $IMVT will deliver best in class data in MG in… https://t.co/A3Mr1KW4fw https://t.co/upIEZcfIyJ
$TRML (-30.5% pre) Tourmaline Bio (TRML) Weakness May be Tied to Negative Results from Chugai's Ensprayng Drug for Myasthenia Gravis - SI https://t.co/6B9ugULMUj
$ARGX (+12.1% pre) Roche falls, Argenx (ARGX) gains after Chugai's Ensprayng drug for myasthenia gravis fails - SI https://t.co/YsUsgpPY8l
$TRML down in pre-market. FcRn companies up $ARGX $IMVT https://t.co/jnb9OYHyHS
Roche / Chugai report disappointing results from Enspryng study in myasthenia gravis. Positive for $ARGX "Statistically significant data was observed in the primary endpoint of the phase III LUMINESCE study, however the results did not reach our expectations on the degree of…
After Opdivo flop in liver cancer, Bristol Myers finds Yervoy combo could save lives https://t.co/ac5rvkX4BX
$BMY Yervoy delivers a surprise in CM-9DW after failure seemed a likelier outcome. Somewhat analogous to $AZN Himalaya, but the real test will be vs $RHHBY Tecentriq + Avastin. Via @ApexOnco -> https://t.co/rdNbHQ71lD
In a phase 1b trial in #GastroesophagealCancer, neoadjuvant nivolumab or nivolumab/relatlimab prior chemoradiotherapy were well tolerated and liquid biopsy analyses show that undetectable ctDNA was associated with longer survival @ValsamoA @vincentlamMD https://t.co/UxOEFYjBR8
Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver cancer. https://t.co/yoJPd93KiO https://t.co/yoJPd93KiO
Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial https://t.co/5uC0vGKwxK https://t.co/8RJ0wkIDoa
Ipi/nivo in 1L #HCC is positive! (CheckMate-9DW study). Excited to see the full data soon... https://t.co/NsQDtj9vgh
Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer. https://t.co/jeWV8rWQBH https://t.co/jeWV8rWQBH